Clinical Trial 55016

Tempe, AZ 85283


Summary:

A Phase 3, 24-week, Randomized,
Placebo-controlled, Double-blind Study to
Assess the Effect of Rocatinlimab on Vaccine
Antibody Response in Adult Subjects With
Moderate-to-severe Atopic Dermatitis (AD)
(ROCKET – VOYAGER)


Qualified Participants Must:

• Must Be 18-54 years
• Been Diagnosed with moderate to severe Atopic Dermatitis
• Have inadequate response to Topical Cortico Steroids


Qualified Participants May Receive:

$100 per visit and study related care and medicine


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.